What the trial was testing
The LEX-209 enrolled 208 patients with anticoagulation reversal. The study was sponsored by Octapharma and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Equal performance — 94% effective bleeding control with either product.
JAMA Network Open · 2024 · NCT02740335
These findings — that bleeding control on either 4-factor prothrombin complex concentrate before urgent surgery — were published in the JAMA Network Open and represent the headline result of the study.
Researchers tracked outcomes across 208 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with anticoagulation reversal, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Both Kcentra and Octaplex are FDA-approved and available now for rapid warfarin reversal in urgent surgery situations. Hospital pharmacies stock one or the other. Ask the surgical team if you need warfarin reversed quickly — speed matters.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open anticoagulation reversal trials
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.